The Cancer Research Alliance, an organization comprised of 12 of the nation's best cancer centers including Moffitt Cancer Center, is asking all 303 million Americans to exercise their power over cancer by stepping up and donating $1 to cancer research efforts this Mother's Day through Father's Day.
"The American Association of Clinical Endocrinologists applauds the FDA's efforts to protect the safety of children and adolescents who are using insulin pumps," said Dr. Richard Hellman, the Association's President.
Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated clinically relevant features addressing abuse liability alongside a promising safety and efficacy profile. The Phase I and II studies, presented at the 27th Annual Scientific Session of the American Pain Society, examined the effects of ALO-01 when crushed -- a common method of abuse -- among recreational drug users and when taken whole, as intended, by chronic pain patients.
Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, announced today that two studies to be presented this week at the American Pain Society annual meeting demonstrate the efficacy, tolerability and positive pharmacokinetic profile of Alpharma Pharmaceuticals' FLECTOR(R) Patch (diclofenac epolamine topical patch) 1.3%, the first and only prescription anti-inflammatory pain relief patch in the United States. FLECTOR(R) Patch has been available since January in the United States for the topical treatment of acute pain due to minor strains, sprains and contusions.
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and commercial partner Meda Pharmaceuticals will present today and tomorrow, data from Phase III clinical pivotal trials for BEMA(TM) Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer. The presentations will be made at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.
Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, according to data presented at the 27th annual meeting of the American Pain Society (APS) in Tampa, Fla.
XenaCare Holdings Inc. (OTCBB: XCHO) announced today, after an 8-month development program, the official launch of their new product called the SunPill(R).
Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on investigational tapentadol immediate release (IR), a novel centrally acting oral analgesic, will be presented for the first time at APS.
A new imaging device, ei-Nav/Artemis(TM), now officially cleared by the U.S. Food and Drug Administration (FDA), offers urologists breakthrough technology that will significantly help in the fight against prostate cancer. Artemis, designed by Eigen, a Northern California-based company known for developing innovative, affordable medical imaging solutions, will be introduced at the American Urological Association's (AUA) annual meeting May 17 - 22 in Orlando, FL.
RTI Biologics Inc. (RTI) (NASDAQ: RTIX), a leading processor of orthopedic and other biologic implants, announced today that the company's revenues were $29.9 million for the first quarter of 2008, compared to $22.0 million for the first quarter 2007.
NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it plans to release its first quarter 2008 financial results on Wednesday, May 7, 2008.
Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced its 2008 first quarter earnings release date. Separately, Noven also announced an upcoming investor presentation.
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced that four scientific posters for its lead product, BEMA(TM) Fentanyl, currently under review by the U.S. Food and Drug Administration (FDA) as a potential treatment for breakthrough pain (BTP) in opioid-tolerant patients with cancer, will be presented at the 27th Annual Scientific Meeting of the American Pain Society (APS), May 8-10, in Tampa, Florida. The scientific presentations will highlight the Phase III efficacy and safety data as well as the pharmacokinetics of BEMA(TM) Fentanyl. The posters will be presented on May 8 and 9.
GBI is one of the earliest biopharmaceutical contract manufacturing organizations (CMOs), established in 1992. GBI specializes in process development and cGMP compliant mammalian cell culture manufacturing of bio-therapeutics for pre-clinical studies through Phase III clinical trials. The company and its predecessor, The Goodwin Institute for Cancer Research, have been operating in the biologics CMO sector since the early 1980's. GBI's clients include small to midsized biotech companies throughout North America and Europe, universities, renowned cancer research institutes and various branches of the U.S. government. GBI was acquired in 2004 by Wallace Pharmaceuticals Pvt. Ltd., a multi-specialty pharmaceutical manufacturer and distributor based in Goa, India. GBI and Wallace together offer clients the experience of an established US Contract Manufacturing Organization together with the potential for timeline and cost-effective scale up manufacturing in India.
Solei Systems, Inc. (Pink Sheets: SOLI) (the "Company") announced today that their stock is now up and trading on the Pink Sheets. The stock is now quoted under ticker symbol "SOLI". Filings are complete at PinkSheets.com. From this point Solei will continue on toward becoming a fully reporting Company and a senior exchange listing.
MiMedx Group, Inc. (OTC Bulletin Board: MDXG) announced today that Ronald G. Wallace, former President of UPS International, has been appointed to its Board of Directors, effective April 29, 2008.
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that its Vice President of Marketing & Sales, W. Neil Jones, has indicated that he plans to leave the company in order to pursue other interests. Jones will remain with Noven for a transition period through the end of May 2008. Noven is working with a national executive recruiting firm to identify Jones's successor.
Jupiter Medical Center (JMC) and the University of Miami (UM) Miller School of Medicine today announced an affiliation agreement that brings northern Palm Beach County access to an academic medical center with the resources and levels of specialty care traditionally available only at a major university teaching hospital.
A change in Chinese meat consumption habits since 1995 is diverting eight billion bushels of grain per year to livestock feed and could empty global grain stocks by September 2010, according to a new study from Biofuels Digest.
Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), announced today that SURGEX(TM) has become the official sports nutrition drink of The Edge Training Facility, www.edgebasketball.com, Florida's premier basketball training facility for NBA stars and young emerging basketball talent. Dee Brown, former Boston Celtic, Orlando Magic Toronto Raptor player, winner of the "no look" 1991 Slum Dunk Contest and WNBA Head Coach, is the CEO and head instructor at The Edge Training Facility. At the Edge Training Facility he and his experienced instructors work with current NBA stars and young basketball players to improve their strength and basketball skills.
